AbbVie Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
AbbVie Inc. (ABBV) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.01 billion for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2019-02-27
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$4.30B.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was -$1.46B.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-12-31 was -$297.00M, a 111.81% decline year-over-year.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-09-30 was $745.00M.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was -$1.01B.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$274.00M.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$6.07B.
- AbbVie Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$12.94B.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$1.01B 10-K · filed 2019-02-27 | |||
| 2017-12-31 | -$274.00M 10-K · filed 2019-02-27 | |||
| 2016-12-31 | -$6.07B 10-K · filed 2019-02-27 | |||
| 2016-06-30 | -$4.30B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$5.76B 10-Q · filed 2016-08-05 | -$6.05B derived: sum of 3 quarters · filed 2018-02-16 | -$5.31B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | -$1.46B 10-Q · filed 2016-05-06 | -$1.75B derived: sum of 2 quarters · filed 2018-02-16 | -$1.01B derived: sum of 3 quarters · filed 2018-02-16 | -$13.52B derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$297.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $448.00M derived: sum of 2 quarters · filed 2018-02-16 | -$12.06B derived: sum of 3 quarters · filed 2018-02-16 | -$12.94B 10-K · filed 2018-02-16 |
| 2015-09-30 | $745.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$11.77B derived: sum of 2 quarters · filed 2016-08-05 | -$12.64B 10-Q · filed 2015-11-06 | -$10.13B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$12.51B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$13.38B 10-Q · filed 2016-08-05 | -$10.87B derived: sum of 3 quarters · filed 2017-02-17 | -$13.15B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$873.00M 10-Q · filed 2016-05-06 | $1.64B derived: sum of 2 quarters · filed 2017-02-17 | -$643.00M derived: sum of 3 quarters · filed 2017-02-17 | -$1.00B derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $2.51B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $230.00M derived: sum of 2 quarters · filed 2017-02-17 | -$129.00M derived: sum of 3 quarters · filed 2017-02-17 | -$926.00M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$2.28B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$2.64B derived: sum of 2 quarters · filed 2015-11-06 | -$3.44B 10-Q · filed 2015-11-06 | -$3.32B derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | -$359.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$1.16B 10-Q · filed 2015-08-07 | -$1.03B derived: sum of 3 quarters · filed 2016-02-19 | -$2.00B derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | -$797.00M 10-Q · filed 2015-05-08 | -$674.00M derived: sum of 2 quarters · filed 2016-02-19 | -$1.64B derived: sum of 3 quarters · filed 2016-02-19 | -$1.41B derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $123.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$841.00M derived: sum of 2 quarters · filed 2016-02-19 | -$608.00M derived: sum of 3 quarters · filed 2016-02-19 | $879.00M 10-K · filed 2016-02-19 |
| 2013-09-30 | -$964.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$731.00M derived: sum of 2 quarters · filed 2014-11-07 | $756.00M 10-Q · filed 2014-11-07 | $550.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-06-30 | $233.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.72B 10-Q · filed 2014-08-07 | $1.51B derived: sum of 3 quarters · filed 2015-02-20 | -$292.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-03-31 | $1.49B 10-Q · filed 2014-05-09 | $1.28B derived: sum of 2 quarters · filed 2015-02-20 | -$525.00M derived: sum of 3 quarters · filed 2015-02-20 | -$727.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2012-12-31 | -$206.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | -$2.01B derived: sum of 2 quarters · filed 2015-02-20 | -$2.21B derived: sum of 3 quarters · filed 2015-02-20 | -$2.42B 10-K · filed 2015-02-20 |
| 2012-09-30 | -$1.81B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$2.01B derived: sum of 2 quarters · filed 2013-11-12 | -$2.21B 10-Q · filed 2013-11-12 | |
| 2012-06-30 | -$202.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$406.00M 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | -$204.00M 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | $553.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |